60330-35-0

Usage

Uses

Used in Pharmaceutical Industry:
7-(TRIFLUOROMETHYL)-1H-INDAZOL-3-YLAMINE is used as a potential kinase inhibitor for the development of targeted cancer therapies. Its unique structure and the presence of the trifluoromethyl group enhance the lipophilicity and metabolic stability of the compound, making it a promising candidate for drug development.
Additionally, 7-(TRIFLUOROMETHYL)-1H-INDAZOL-3-YLAMINE can be used in the synthesis of other related compounds with potential therapeutic applications, further contributing to the advancement of medicinal chemistry and drug discovery.

Upstream product

• 146070-35-1 2-fluoro-3-(trifluoromethyl)benzonitrile 

Relevant academic research and scientific papers

(AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

GLUCOKINASE ACTIVATORS

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of wherein the variables are as defined herein.